English version All offices All contacts Home About Sobi Investors & Media Products Sobi has a diversified product portfolio with good growth in the three product areas: Core products, Partner products and ReFacto manufacturing. For more information about our product areas (English version). Research portfolio Our research portfolio includes three programs in late clinical trials, of which two in hemophilia and one in neonatology. For more information about our research portfolio (English version). Annual General Meeting Annual General Meeting of Swedish Orphan Biovitrum AB (publ), orgnr. 556038-9321 took place on Thursday, May 8, 2014 in the Wallenberg Hall at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm. More information about the Annual General Meeting Sobi's quarterly report April - June 2014 published July 18, 2014 - Revenues for the quarter amounted to a total of SEK 663 M (520), an increase of 27 percent. To interim report quarter 2 2014 To the Annual Report 2013 To financial reports For presentations Stock price SEK 68.00 SEK 0.10 Percent 0.15% Volume: 838,101 Short name: SOBI List: SSE Large More information about the share News Reports View: All News Press release Sobi's partner Biogen Idec applies for market approval for Elocta (TM) (rFVII ... 2014-10-09 21:00 in Press releases Sobi inaugurates the North American office 2014-09-22 17:00 in Press releases Sobi expands development portfolio in hemophilia - chooses to include potentially long-term ... 2014-09-19 08:00 in Press releases Change in the number of shares and votes in Swedish Orphan Biovitrum AB (publ) 2014-07-31 08:00 in Press releases More news Contact Swedish Orphan Biovitrum AB (publ), SE-112 76 Stockholm Phone : +46 8 697 20 00 Reg.No. 556038-9321 Quick links Contacts and addresses (English version) follow us Press release News Financial reports